StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
3
Publishing Date
2023 - 01 - 17
1
2022 - 05 - 03
1
2021 - 09 - 08
1
Sector
Health technology
3
Tags
Alliances
1
Als
3
America
2
Announces collaboration
1
Biocanada
13
Biopharma
2
Bioscience
1
Biotech
4
Biotechnology
3
Care
1
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
1
Collaboration
2
Commercial
1
Company announcement
1
Conference
33
Congress
1
Dravet syndrome
1
Drug
1
Earnings
1
Events
2
Expansion
1
Fda
1
Financial
11
Financial results
6
Ford
1
Genetown
1
Global
4
Growth
1
Health
2
International
1
Iot
1
Key
1
Major depressive disorder
1
Market
1
Meeting
5
Milestone
5
N/a
61
Neurology
1
Offering
8
People
2
Pharmaceuticals
43
Phase 2
6
Phase 2b
3
Pipeline
1
Positive
3
Pre-clinical
1
Preclinical
1
Program
4
Publication
3
Report
1
Research
2
Results
22
Svb leerink global
1
Topline
2
Treatment
3
Trial
8
Update
14
Xen1101
9
Year
4
Entities
Abbvie inc.
1
Jazz pharmaceuticals plc
1
Neurocrine biosciences, inc.
1
Thermo fisher scientific inc
1
Viatris inc.
1
Xenon pharmaceuticals inc.
3
Symbols
ABBV
117
ABT
56
ADMP
19
ALNY
38
ALPMF
50
ALPMY
50
AMGN
46
ARQT
24
ARWR
21
AZN
46
AZNCF
38
BHC
35
BIIB
41
BMY
93
BSX
21
BTAI
19
BWAY
39
CHRS
28
CNSP
26
ECL
47
FBIO
27
FNCTF
84
GILD
50
GLAXF
73
GSK
98
HOTH
24
HZNP
19
INCY
77
IONS
19
JNJ
196
KPTI
27
LLY
175
MBRX
28
MDT
44
MMM
20
MNOV
24
MRK
63
NRXP
19
NTLA
31
NVO
34
NVS
137
NVSEF
113
PFE
73
PHG
20
RARE
25
REGN
57
RETA
28
RGNX
25
SNGX
19
SNY
277
SNYNF
229
SRNE
37
TAK
50
TEVJF
76
TGTX
24
TNXP
29
VRCA
23
VRTX
27
VTRS
45
XYL
35
Exchanges
Nasdaq
3
Nyse
1
Crawled Date
2023 - 01 - 17
1
2022 - 05 - 03
1
2021 - 09 - 08
1
Crawled Time
14:00
1
19:00
2
Source
www.biospace.com
2
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
symbols :
XENE
save search
Dravet syndrome treatment market size to increase by USD 575.14 million; North America to contribute 38% of market growth - Technavio
Published:
2023-01-17
(Crawled : 19:00)
- prnewswire.com
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
|
-4.98%
|
O:
-0.17%
H:
0.25%
C:
-2.96%
TMO
|
News
|
$544.78
0.6%
0.0%
1.7M
|
Health Technology
|
-7.33%
|
O:
0.56%
H:
0.97%
C:
-1.87%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
8.89%
|
O:
-0.46%
H:
0.2%
C:
-1.92%
XENE
|
$39.91
-0.99%
-1.0%
360K
|
Health Technology
|
10.17%
|
O:
-0.17%
H:
1.88%
C:
-0.58%
JAZZ
|
$109.96
0.63%
0.63%
760K
|
Health Technology
|
-29.43%
|
O:
-0.46%
H:
1.9%
C:
-0.12%
america
treatment
growth
market
dravet syndrome
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
Published:
2022-05-03
(Crawled : 19:00)
- biospace.com/
XENE
|
$39.91
-0.99%
-1.0%
360K
|
Health Technology
|
37.28%
|
O:
-0.22%
H:
0.0%
C:
0.0%
xen1101
treatment
trial
phase 2
major depressive disorder
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021
Published:
2021-09-08
(Crawled : 14:00)
- biospace.com/
XENE
|
$39.91
-0.99%
-1.0%
360K
|
Health Technology
|
125.44%
|
O:
0.06%
H:
1.98%
C:
-2.94%
NBIX
M
|
$132.03
-0.39%
-0.39%
560K
|
Health Technology
|
40.83%
|
O:
-0.62%
H:
1.8%
C:
1.72%
treatment
phase 2
collaboration
announces collaboration
trial
milestone
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.